ViaCyte has obtained $10 million in financing to fund the clinical development of its stem cell-derived treatment for type 1 diabetes. The treatment uses stem cell-derived pancreatic cells in an implantable device. The cells are designed to mature into human pancreatic cells, including insulin-secreting beta cells. Read more